Literature DB >> 33543455

Radiolabeling of Theranostic Nanosystems.

Sudeep Das1, Surachet Imlimthan1, Anu J Airaksinen1,2, Mirkka Sarparanta3.   

Abstract

In the recent years, progress in nanotechnology has significantly contributed to the development of novel pharmaceutical formulations to overcome the drawbacks of conventional treatments and improve the therapeutic outcome in many diseases, especially cancer. Nanoparticle vectors have demonstrated the potential to concomitantly deliver diagnostic and therapeutic payloads to diseased tissue. Due to their special physical and chemical properties, the characteristics and function of nanoparticles are tunable based on biological molecular targets and specific desired features (e.g., surface chemistry and diagnostic radioisotope labeling). Within the past decade, several theranostic nanoparticles have been developed as a multifunctional nanosystems which combine the diagnostic and therapeutic functionalities into a single drug delivery platform. Theranostic nanosystems can provide useful information on a real-time systemic distribution of the developed nanosystem and simultaneously transport the therapeutic payload. In general, the diagnostic functionality of theranostic nanoparticles can be achieved through labeling gamma-emitted radioactive isotopes on the surface of nanoparticles which facilitates noninvasive detection using nuclear molecular imaging techniques, such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT), meanwhile, the therapeutic effect arises from the potent drug released from the nanoparticle. Moreover, some radioisotopes can concurrently emit both gamma radiation and high-energy particles (e.g., alpha, beta, and Auger electrons), prompting the use either alone for radiotheranostics or synergistically with chemotherapy. This chapter provides an overview of the fundamentals of radiochemistry and relevant radiolabeling strategies for theranostic nanosystem development as well as the methods for the preclinical evaluation of radiolabeled nanoparticles. Furthermore, preclinical case studies of recently developed theranostic nanosystems will be highlighted.

Entities:  

Keywords:  Molecular imaging; Nanotheranostic; Nuclear imaging; Radiochemistry; Radiolabeling; Theranostic nanosystem

Year:  2021        PMID: 33543455     DOI: 10.1007/978-3-030-58174-9_3

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  60 in total

Review 1.  Matching chelators to radiometals for radiopharmaceuticals.

Authors:  Eric W Price; Chris Orvig
Journal:  Chem Soc Rev       Date:  2013-10-30       Impact factor: 54.564

Review 2.  Theranostic and nanotheranostic probes in nuclear medicine.

Authors:  Natascha Drude; Lena Tienken; Felix M Mottaghy
Journal:  Methods       Date:  2017-07-08       Impact factor: 3.608

3.  Theranostic Nanosystems for Targeted Cancer Therapy.

Authors:  Homan Kang; Shuang Hu; Mi Hyeon Cho; Suk Ho Hong; Yongdoo Choi; Hak Soo Choi
Journal:  Nano Today       Date:  2018-11-16       Impact factor: 20.722

Review 4.  Small Prosthetic Groups in 18F-Radiochemistry: Useful Auxiliaries for the Design of 18F-PET Tracers.

Authors:  Ralf Schirrmacher; Björn Wängler; Justin Bailey; Vadim Bernard-Gauthier; Esther Schirrmacher; Carmen Wängler
Journal:  Semin Nucl Med       Date:  2017-07-17       Impact factor: 4.446

Review 5.  Consensus nomenclature rules for radiopharmaceutical chemistry - Setting the record straight.

Authors:  Heinz H Coenen; Antony D Gee; Michael Adam; Gunnar Antoni; Cathy S Cutler; Yasuhisa Fujibayashi; Jae Min Jeong; Robert H Mach; Thomas L Mindt; Victor W Pike; Albert D Windhorst
Journal:  Nucl Med Biol       Date:  2017-10-02       Impact factor: 2.408

6.  Single agent nanoparticle for radiotherapy and radio-photothermal therapy in anaplastic thyroid cancer.

Authors:  Min Zhou; Yunyun Chen; Makoto Adachi; Xiaoxia Wen; Bill Erwin; Osama Mawlawi; Stephen Y Lai; Chun Li
Journal:  Biomaterials       Date:  2015-04-24       Impact factor: 12.479

Review 7.  Positron emission tomography microdosing: a new concept with application in tracer and early clinical drug development.

Authors:  Mats Bergström; Anders Grahnén; Bengt Långström
Journal:  Eur J Clin Pharmacol       Date:  2003-08-22       Impact factor: 2.953

Review 8.  Radioimmunotherapy of cancer with high linear energy transfer (LET) radiation delivered by radionuclides emitting α-particles or Auger electrons.

Authors:  Sadaf Aghevlian; Amanda J Boyle; Raymond M Reilly
Journal:  Adv Drug Deliv Rev       Date:  2015-12-17       Impact factor: 15.470

Review 9.  Monoclonal Antibodies Radiolabeling with Rhenium-188 for Radioimmunotherapy.

Authors:  Licia Uccelli; Petra Martini; Micol Pasquali; Alessandra Boschi
Journal:  Biomed Res Int       Date:  2017-08-30       Impact factor: 3.411

Review 10.  Auger electrons for cancer therapy - a review.

Authors:  Anthony Ku; Valerie J Facca; Zhongli Cai; Raymond M Reilly
Journal:  EJNMMI Radiopharm Chem       Date:  2019-10-11
View more
  1 in total

Review 1.  Radiolabeling of Nanomaterials: Advantages and Challenges.

Authors:  Wanqin Dai; Junzhe Zhang; Yun Wang; Chunlei Jiao; Zhuda Song; Yuhui Ma; Yayun Ding; Zhiyong Zhang; Xiao He
Journal:  Front Toxicol       Date:  2021-12-13
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.